Zymeworks Common Stock Stock Today
| ZYME Stock | USD 14.50 0.41 2.91% |
Performance9 of 100
| Odds Of DistressLess than 21
|
Zymeworks Common is trading at 14.50 as of the 2nd of December 2024, a 2.91 percent up since the beginning of the trading day. The stock's lowest day price was 14.11. Zymeworks Common has about a 21 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Zymeworks Common Stock are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of December 2022 and ending today, the 2nd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of April 2017 | Category Healthcare | Classification Health Care |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. Zymeworks operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. The company has 68.88 M outstanding shares of which 4.21 M shares are at this time shorted by private and institutional investors with about 7.54 trading days to cover. More on Zymeworks Common Stock
Moving against Zymeworks Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Zymeworks Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Ali Tehrani | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Zymeworks Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsZymeworks Common can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Zymeworks Common's financial leverage. It provides some insight into what part of Zymeworks Common's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Zymeworks Common Stock (ZYME) is traded on NASDAQ Exchange in USA. It is located in 108 Patriot Drive, Middletown, DE, United States, 19709 and employs 294 people. Zymeworks Common is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 993.21 M. Zymeworks Common Stock conducts business under Biotechnology sector and is part of Health Care industry. The entity has 68.88 M outstanding shares of which 4.21 M shares are at this time shorted by private and institutional investors with about 7.54 trading days to cover.
Zymeworks Common Stock currently holds about 241.83 M in cash with (118.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18.
Check Zymeworks Common Probability Of Bankruptcy
Ownership AllocationZymeworks Common Stock retains a total of 68.88 Million outstanding shares. The majority of Zymeworks Common outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zymeworks Common Stock to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zymeworks Common Stock. Please pay attention to any change in the institutional holdings of Zymeworks Common Stock as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Zymeworks Ownership Details
Zymeworks Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Farallon Capital Management, L.l.c. | 2024-09-30 | 1.4 M | |
| State Street Corp | 2024-09-30 | 1.2 M | |
| Nextech Invest Ag | 2024-09-30 | 1.1 M | |
| Tang Capital Management Llc | 2024-09-30 | 1.1 M | |
| Samsara Biocapital, Llc | 2024-09-30 | 1000 K | |
| Prosight Management, Lp | 2024-09-30 | 917.6 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 849.5 K | |
| Bridgeway Capital Management, Llc | 2024-09-30 | 742.6 K | |
| Geode Capital Management, Llc | 2024-09-30 | 713.9 K | |
| Ecor1 Capital, Llc | 2024-09-30 | 13.4 M | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 5.1 M |
Zymeworks Common Historical Income Statement
Zymeworks Stock Against Markets
Zymeworks Common Corporate Directors
| Thomas Kreudenstein | Director Engineering | Profile | |
| Nina Weisser | Director Therapeutics | Profile | |
| Lota Zoth | Lead Independent Director | Profile | |
| Shrinal Inamdar | Director Relations | Profile |
Already Invested in Zymeworks Common Stock?
The danger of trading Zymeworks Common Stock is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zymeworks Common is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zymeworks Common. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zymeworks Common Stock is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.